Brazil signs COVID-19 vaccine deal with Bharat Biotech

The first batch of Covazin shots to arrive in March

Updated - February 26, 2021 09:07 am IST - Sao Paulo

Union Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi. File photo

Union Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi. File photo

On the same day Brazil reached the grim milestone of 250,000 deaths by COVID-19 , the country's health ministry signed a deal with Indian pharmaceutical company Bharat Biotech for the purchase of 20 million doses of the Covaxin Vaccines , which is yet to be approved by local regulators.

The administration of President Jair Bolsonaro said the first 8 million Covaxin shots, which will be made by Brazilian company Precisa Medicamentos, will arrive in March. A second batch of another 8 million doses is expected for April and in May, another 4 million doses will be available.

Also read: Brazilian President invokes Ramayana while seeking hydroxychloroquine from India

So far Brazil has vaccinated less than 4 per cent of its population of 210 million people, with some cities stopping immunization campaigns last week due to shortages.

Neither Precisa nor Bharat confirmed the deal or the delivery dates.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.